Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Anurag Verma, Juhi Dubey, Rahul Rama Hegde, Vaibhav Rastogi & J. K. Pandit. (2016) Helicobacter pylori: past, current and future treatment strategies with gastroretentive drug delivery systems. Journal of Drug Targeting 24:10, pages 897-915.
Read now
Read now
Articles from other publishers (48)
Rui Zhang, Pengpeng Guo, Jinping Zhou, Peixia Li, Jing Wan, Chunxiao Yang, Jiali Zhou, Yani Liu & Shaojun Shi. (2023) Pharmacokinetics and bioequivalence evaluation of omeprazole and sodium bicarbonate dry suspensions in healthy Chinese volunteers. Scientific Reports 13:1.
Crossref
Crossref
Angelo Zullo. (2020) The current role of dual therapy for treatment of Helicobacter pylori: back to the future?. European Journal of Gastroenterology & Hepatology 32:5, pages 555-556.
Crossref
Crossref
Vincenzo De Francesco, Angelo Zullo, Giulia Fiorini, Ilaria M Saracino, Matteo Pavoni & Dino Vaira. (2019)
Role of MIC levels of resistance to clarithromycin and metronidazole in
Helicobacter pylori
eradication
. Journal of Antimicrobial Chemotherapy 74:3, pages 772-774.
Crossref
Crossref
Ferdane Sapmaz, Ismail Hakki Kalkan, Sefa Güliter & Pınar Atasoy. (2014) Comparison of Helicobacter pylori eradication rates of standard 14-day quadruple treatment and novel modified 10-day, 12-day and 14-day sequential treatments. European Journal of Internal Medicine 25:3, pages 224-229.
Crossref
Crossref
Mounia Lahbabi, Samia Alaoui, Karima El Rhazi, Mohammed El Abkari, Chakib Nejjari, Afaf Amarti, Bahia Bennani, Mustapha Mahmoud, Adil Ibrahimi & Dafr Allah Benajah. (2013) Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: Result of the HPFEZ randomised study. Clinics and Research in Hepatology and Gastroenterology 37:4, pages 416-421.
Crossref
Crossref
Norihiro Furusyo, Ahmed H. Walaa, Kunimitsu Eiraku, Kazuhiro Toyoda, Eiichi Ogawa, Hiroaki Ikezaki, Takeshi Ihara, Takeo Hayashi, Mosaburo Kainuma, Masayuki Murata & Jun Hayashi. (2011) Treatment for Eradication of Helicobacter pylori Infection among Chronic Hepatitis C Patients. Gut and Liver 5:4, pages 447-453.
Crossref
Crossref
Jong In KimByung-Wook Kim. (2011)
Sequential Therapy of
Helicobacter pylori
Infection
. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 11:2, pages 103.
Crossref
Crossref
David Forman, Franco Bazzoli, Cathy Bennett, Nathalie Broutet, Naoki Chiba, Jonathan J Deeks, Carlo Fallone, Lori Fischbach, Richard Hunt, Raymond Lahaie, Robert Laheij, Francis Megraud, Paul Moayyedi, Giuseppina Oderda, Domenico Palli, Vincenzo Savarino, George (JJ) Misiewicz, Peter Unge, Javier P Gisbert, Ernst J Kuipers, Xavier Calvet, Adam Harris & J Q Huang. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Chise Kodaira, Mitsushige Sugimoto, Masafumi Nishino, Mihoko Yamade, Naohito Shirai, Shinya Uchida, Mutsuhiro Ikuma, Shizuo Yamada, Hiroshi Watanabe, Akira Hishida & Takahisa Furuta. (2009) Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects. European Journal of Clinical Pharmacology 65:6, pages 593-600.
Crossref
Crossref
Jorge Luis Poo, Juan Francisco Galán, Alejandra Rosete, Alberto de Lago, Iván Oliva, Mario González-de la Parra, Patricia Jiménez, Victoria Burke-Fraga & Salvador Namur. (2008) Bioavailability of Two Single-Dose Oral Formulations of Omeprazole 20 mg: An Open-Label, Randomized Sequence, Two-Period Crossover Comparison in Healthy Mexican Adult Volunteers. Clinical Therapeutics 30:4, pages 693-699.
Crossref
Crossref
Javier P. Gisbert, Ramón Pajares & José María Pajares. (2007) Evolution of Helicobacter pylori Therapy from a Meta-analytical Perspective. Helicobacter 12:s2, pages 50-58.
Crossref
Crossref
Takahisa FurutaMitsushige Sugimoto, Naohito Shirai & Takashi Ishizaki. (2007)
CYP2C19
pharmacogenomics associated with therapy of
Helicobacter pylori
infection and gastro-esophageal reflux diseases with a proton pump inhibitor
. Pharmacogenomics 8:9, pages 1199-1210.
Crossref
Crossref
Akiko Nakamura, Takahisa Furuta, Naohito Shirai, Mitsushige Sugimoto, Masayoshi Kajimura, Yoshihiro Soya & Akira Hishida. (2007)
Determination of mutations of the 23S rRNA gene of
Helicobacter pylori
by allele specific primer-polymerase chain reaction method
. Journal of Gastroenterology and Hepatology 22:7, pages 1057-1063.
Crossref
Crossref
Mesut Sancar, Fikret Vehbi Izzettin, Sule Apikoglu-Rabus, Fatih Besisik, Nurdan Tozun & Gul Dulger. (2006) Pharmacoeconomic comparison of Helicobacter pylori eradication regimens. Pharmacy World & Science 28:4, pages 207-214.
Crossref
Crossref
K. Okudaira, T. Furuta, N. Shirai, M. Sugimoto & S. Miura. (2005) Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. Alimentary Pharmacology and Therapeutics 21:4, pages 491-497.
Crossref
Crossref
Yunqi Wu & Reza Fassihi. (2005) Stability of metronidazole, tetracycline HCl and famotidine alone and in combination. International Journal of Pharmaceutics 290:1-2, pages 1-13.
Crossref
Crossref
Takahisa Furuta, Naohito Shirai, Mitsushige Sugimoto, Akiko Nakamura, Akira Hishida & Takashi Ishizaki. (2005) Influence of CYP2C19 Pharmacogenetic Polymorphism on Proton Pump Inhibitor-based Therapies. Drug Metabolism and Pharmacokinetics 20:3, pages 153-167.
Crossref
Crossref
Jia Qing HUANG, Ge Fan ZHENG, E Jan IRVINE & Johan KARLBERG. (2004) Assessing heterogeneity in meta-analyses of Helicobacter pylori infection-related clinical studies: a critical appraisal. Chinese Journal of Digestive Diseases 5:3, pages 126-133.
Crossref
Crossref
FULL-YOUNG CHANG, CHING-LIANG LU, CHIH-YEN CHEN, JIING-CHYUAN LUO, KANG LIH JIUM & SHOU-DONG LEE. (2003) Effect of Helicobacter pylori eradicated therapy on water gastric emptying in patients with active duodenal ulcer. Journal of Gastroenterology and Hepatology 18:11, pages 1250-1256.
Crossref
Crossref
Nicholaos Makris, Ralph Crott, Carlo A. Fallone, Marc Bardou & Alan Barkun. (2003) Cost-effectiveness of routine endoscopic biopsies for Helicobacter pylori detection in patients with non-ulcer dyspepsia. Gastrointestinal Endoscopy 58:1, pages 14-22.
Crossref
Crossref
A. Zullo, D. Vaira, N. Vakil, C. Hassan, L. Gatta, C. Ricci, V. De Francesco, M. Menegatti, A. Tampieri, F. Perna, V. Rinaldi, F. Perri, C. Papadìa, F. Fornari, S. Pilati, L. S. Mete, A. Merla, R. Potì, G. Marinone, A. Savioli, S. M. A. Campo, D. Faleo, E. Ierardi, M. Miglioli & S. Morini. (2003)
High eradication rates of
Helicobacter pylori
with a new sequential treatment
. Alimentary Pharmacology & Therapeutics 17:5, pages 719-726.
Crossref
Crossref
P. Della Monica, A. Lavagna, G. Masoero, L. Lombardo, L. Crocellá & A. Pera. (2002)
Effectiveness of
Helicobacter pylori
eradication treatments in a primary care setting in Italy
. Alimentary Pharmacology & Therapeutics 16:7, pages 1269-1275.
Crossref
Crossref
Lori A Fischbach, Karen J Goodman, Mark Feldman & Corinne Aragaki. (2002) Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis. International Journal of Epidemiology 31:1, pages 128-139.
Crossref
Crossref
F. A. Al‐Eidan, J. C. McElnay, M. G. Scott & J. B. McConnell. (2002)
Management of
Helicobacter pylori
eradication – the influence of structured counselling and follow‐up
. British Journal of Clinical Pharmacology 53:2, pages 163-171.
Crossref
Crossref
A. Bühling, D. Radun, W. A. Müller & P. Malfertheiner. (2001)
Influence of anti-
Helicobacter
triple-therapy with metronidazole, omeprazole and clarithromycin on intestinal microflora
. Alimentary Pharmacology & Therapeutics 15:9, pages 1445-1452.
Crossref
Crossref
Nihal Avcu, Ferit Avcu, Cengiz Beyan, Ali UĞur Ural, Kürş ad Kaptan, Mustafa Özyurt, Oral Nevruz & Atilla Yalçin. (2001) The relationship between gastric-oral Helicobacter pylori and oral hygiene in patients with vitamin B12–deficiency anemia. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 92:2, pages 166-169.
Crossref
Crossref
Takahisa Furuta, Naohito Shirai, Misako Takashima, Fang Xiao, Hiroyuki Hanai, Kazuko Nakagawa, Haruhiko Sugimura, Kyoichi Ohashi & Takashi Ishizaki. (2001) Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 11:4, pages 341-348.
Crossref
Crossref
Wei Hong Wang, Benjamin Chun Yu Wong & Shiu Kum Lam. (2001)
Pooled analysis of
Helicobacter pylori
eradication regimes in Asia
. Journal of Gastroenterology and Hepatology 15:9, pages 1007-1017.
Crossref
Crossref
David Forman, Franco Bazzoli, Cathy Bennett, Nathalie Broutet, Naoki Chiba, Jonathan J Deeks, Carlo Fallone, Lori Fischbach, Richard Hunt, Raymond Lahaie, Robert Laheij, Francis Megraud, Paul Moayyedi, Giuseppina Oderda, Domenico Palli, Vincenzo Savarino, George (JJ) Misiewicz, Peter Unge, Javier P Gisbert, Ernst J. Kuipers, Xavier Calvet, Adam Harris & J Q Huang. 1996. The Cochrane Database of Systematic Reviews. The Cochrane Database of Systematic Reviews.
Maria P. Dore, David Y. Graham, Antonia R. Sepulveda, Giuseppe Realdi & Michael S. Osato. (1999)
Sensitivity of Amoxicillin-Resistant
Helicobacter pylori
to Other Penicillins
. Antimicrobial Agents and Chemotherapy 43:7, pages 1803-1804.
Crossref
Crossref
Giuseppe RealdiMaria P. Dore, Andrea Piana, Antonella AtzeiMonica CartaLuigi CugiaAlessandra Manca, Bianca M. Are, Giovanni Massarelli, Ida Mura, Alessandro Maida & David Y. Graham. (2002)
Pretreatment Antibiotic Resistance in
Helicobacter pylori
Infection: Results of Three Randomized Controlled Studies
. Helicobacter 4:2, pages 106-112.
Crossref
Crossref
B. L. Slomiany, J. Piotrowski & A. Slomiany. (1999) Gastric mucosal inflammatory responses toHelicobacter pylori lipopolysaccharide: Suppression of caspase-3 and nitric oxide synthase-2 by omeprazole and sucralfate. Inflammopharmacology 7:2, pages 163-177.
Crossref
Crossref
Amanda Henry & Robert G Batey. (1999) Enhancing Compliance Not A Prerequisite for Effective Eradication of Helicobacter Pylori : The Help Study. American Journal of Gastroenterology 94:3, pages 811-815.
Crossref
Crossref
Seiichi KatoHideyo RitsunoKenji OhnumaKazuie IinumaToshiro Sugiyama & Masahiro Asaka. (2006)
Safety and Efficacy of One‐Week Triple Therapy for Eradicating
Helicobacter pylori
in Children
. Helicobacter 3:4, pages 278-282.
Crossref
Crossref
David M. Israel & Eric Hassall. (1998) Omeprazole and Other Proton Pump Inhibitors: Pharmacology, Efficacy, and Safety, with Special Reference to Use in Children. Journal of Pediatric Gastroenterology & Nutrition 27:5, pages 568-579.
Crossref
Crossref
Philip E. Coudron & Charles W. Stratton. (1998) The bactericidal activity of clarithromycin versus ampicillin alone and in combination with omeprazole and/or bismuth against clarithromycin-susceptible and clarithromycin-resistant strains of Helicobacter pylori. Diagnostic Microbiology and Infectious Disease 32:1, pages 39-44.
Crossref
Crossref
B.L. Slomiany, J. Piotrowski, Slomiany, W. Konturek & W.W. Domschke. (1998) Enhancement in the Protective Qualities of Gastric Mucus with Combination Therapy of Ebrotidine and Amoxicillin for H. pylori Eradication. General Pharmacology: The Vascular System 31:2, pages 227-231.
Crossref
Crossref
Dore, Piana, Carta, Atzei, Are, Mura, Massarelli, Maida, Sepulveda, Graham & Realdi. (1998)
Amoxycillin resistance is one reason for failure of amoxycillin-omeprazole treatment of
Helicobacter pylori
infection
. Alimentary Pharmacology & Therapeutics 12:7, pages 635-639.
Crossref
Crossref
F. Gomollón, J.A. Ducóns, L. Gimeno, J. Fuentes, S. García, J. Vera & M. Montoro. (2001) The Ideal Therapy Must Be Def ined in Each Geographical Area: Experience with a Quadruple Therapy in Spain. Helicobacter 3:2, pages 110-114.
Crossref
Crossref
Blum, Hunt, Kidd, Shi, Jennings & Greski‐Rose. (2001) Dose–response relationship of lansoprazole to gastric acid antisecretory effects. Alimentary Pharmacology & Therapeutics 12:4, pages 321-327.
Crossref
Crossref
M.D. Willard. (1998) Gastrointestinal Drugs. Veterinary Clinics of North America: Small Animal Practice 28:2, pages 377-394.
Crossref
Crossref
D. Y. Graham & M. P. Dore. 1998. Helicobacter pylori. Helicobacter pylori
426
440
.
Charles W. Stratton & Philip E. Coudron. (1997) A practical approach to the diagnosis and therapy of helicobacter pylori infection. Antimicrobics and Infectious Diseases Newsletter 16:11, pages 81-86.
Crossref
Crossref
B E DunnH CohenM J Blaser. (1997) Helicobacter pylori. Clinical Microbiology Reviews 10:4, pages 720-741.
Crossref
Crossref
JIA-QING HUANG & RICHARD H HUNT. (1997) Review: Eradication of Helicobacter pylori. Problems and recommendations. Journal of Gastroenterology and Hepatology 12:8, pages 590-598.
Crossref
Crossref
Takuya Takimoto, Kiichi Satoh, Yushi Taniguchi, Koji Saifuku, Ken Kihira, Masaru Seki, Yukio Yoshida, Kenichi Ido & Ken Kimura. (2008)
The Efficacy and Safety of One‐Week Triple Therapy with Lansoprazole, Clarithromycin, and Metronidazole for the Treatment of
Helicobacter pylori
Infection in Japanese Patients
. Helicobacter 2:2, pages 86-91.
Crossref
Crossref
KWONG MING FOCK. (2008) Peptic ulcer disease in the 1990s: An Asian perspective. Journal of Gastroenterology and Hepatology 12:6.
Crossref
Crossref
Stephan Miehlke & David Y. Graham. (1997) Antimicrobial therapy of peptic ulcers. International Journal of Antimicrobial Agents 8:3, pages 171-178.
Crossref
Crossref